Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Thrive Care: Internet CBT for Depression

7 marzo 2018 aggiornato da: Kaiser Permanente

The Thrive Care Study: Computer-Delivered Cognitive Behavioral Therapy as Care Augmentation for Depressed Primary Care Patients

This project will study the effectiveness of computerized cognitive behavioral therapy (CBT) in reducing depression symptoms. The design is a two-arm randomized controlled trial comparing (i) control arm, which is treatment as usual with (ii) treatment arm, which is treatment as usual plus computerized CBT. The primary outcome measure is change in depression symptom severity. The name of the computerized CBT program to be used in the study is Thrive.

Panoramica dello studio

Stato

Completato

Condizioni

Intervento / Trattamento

Descrizione dettagliata

Population:

  • As identified in Epic, Kaiser Permanente Southern California (KPSC) Fontana Family Medicine patients with a depression diagnosis recorded during the prior week (rolling basis).
  • Target study enrollment: 150 participants per arm (300 total)

Recruitment:

  • Kaiser Permanente (KP) will send eligible patients a postal letter inviting them to participate in study. Interested patients will be directed to the Enrollment/Assessment Website, a website to be developed by vendor Waypoint Health Innovations. The recruitment letter will contain (i) a description of the study, (ii) the web address for the Enrollment/Assessment Website, (iii) the patient's Study Identifier (ID).
  • Additionally, KP will send eligible patients for whom KP has an email address an email inviting them to participate in the study.

Screening and Enrollment (Enrollment/Assessment Website):

  • A patient interested in applying to the study will visit the Enrollment/Assessment Website and input his/her unique Study ID. The website will verify that the entered Study ID is on a pre-loaded list. If valid, the patient may continue to screening assessments.
  • Patient will complete the 9-item Patient Health Questionnaire (PHQ-9) depression symptom assessment. Patients with eligible PHQ-9 scores may continue to Informed Consent page.
  • The Informed Consent (IC) page will contain (i) the Informed Consent text including contact information for any questions patient may have; (ii) fields for first name, last name, date of birth, email address, and phone number; (iii) a check box labeled "I understand the above information and agree to participate…" (or similar); and (iv) a "submit" (or similar) button.
  • To enroll in the study, the patient must complete all fields, check the box, and click submit button. The website will validate that every field has been completed and that the phone number and email fields have the correct format (e.g. name@domain.com for the email field).
  • If all fields are complete, the website will store the Study ID, first name, last name, date of birth, email address, and phone number that patient entered into the website. They will be stored in an encrypted database for use by researchers.
  • Additionally, the website will store the complete Informed Consent page (including Informed Consent text, first name, last name, date of birth, email address, phone number, and checked box) in a single encrypted record, timestamp it, and place a digital certificate on it. The digital certificate will allow us to prove that no one tampered with any part of the IC document after the participant clicked submit.
  • The website automatically randomizes participants to treatment or control arm. Participants continue in website to baseline assessments.
  • After baseline assessments, control arm participants go to a page in the Enrollment/Assessment Website telling them to expect assessment again in 2 months, while treatment arm participants will be given instructions for enrolling in Thrive.
  • Researchers would have access to the completed IC forms to print and/or mail to patients who request a copy.
  • Weekly, KP research coordinator will review new participants' study ID, name, and date of birth (DOB) the participant entered to ensure they match KP records. Individuals who entered information that does not reasonably match KP records would be removed from the study.

Coaching:

• KP will send each treatment arm participant four emails encouraging them to use Thrive, with the exception that the second email will be replaced by a phone call from KP for patients who have not achieved a minimum level of activity in Thrive at that point.

Endpoint and Follow-up Assessments:

• KP will ask each study participant to visit Enrollment/Assessment Website 2 and 6 months after study enrollment to complete assessments.

Tipo di studio

Interventistico

Iscrizione (Effettivo)

304

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

    • California
      • Fontana, California, Stati Uniti, 92335
        • Kaiser Fontana Medical Center

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  • Per EPIC (or other system) records, clinical depression was addressed during the prior week by a KPSC Fontana Family Medicine physician , reflected by an ICD-9 or ICD-10 diagnosis of Depression, Major Depressive Disorder, Dysthymia, Adjustment Disorder with Depressed Mood, and Depression Not Otherwise Specified. This does not have to be the patient's first depression diagnosis.
  • Screening Patient Health Questionnaire (PHQ-9) score of ≥5 as measured in Assessment Website (see Section 4 for information on Assessment Website)

Exclusion Criteria:

  • History or current diagnosis indicating any Schizophrenia spectrum or other psychotic disorder, any Neurocognitive disorder, Delirium, Bipolar disorder, Intellectual disability, or Personality disorder, or any active substance abuse, as defined by DSM-5
  • Member is not proficient in English
  • Member answered "more than half the days" or "nearly every day" on the Patient Health Questionnaire ninth item and did not subsequently answer (regarding suicidal ideations) "Yes" to the question "are you sure you can stay safe?"

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Separare

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Nessun intervento: Control Arm
After enrollment in the study, the subject will continue to receive treatment as usual for their depression from their primary care physician. They then will be asked to complete 2-month and 6-month assessments about their emotional well-being.
Sperimentale: Intervention Arm
After enrollment in the study, the subject will be granted 8 weeks of access to "Thrive", an online self-help tool designed to assess for depressive symptoms and give therapeutic suggestions based on Cognitive Behavioral Therapy. During the first 4 weeks, they will receive 4 coaching emails and/or phone calls encouraging their participation in the study, and answering any program-related questions. The subject will also continue to receive treatment as usual for their depression from their primary care physician. They then will be asked to complete 2-month and 6-month assessments about their emotional well-being.
Thrive is an online self-help tool designed to assess for depressive symptoms and give therapeutic suggestions based on Cognitive Behavioral Therapy principals.
Altri nomi:
  • Thrive for Depression

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
PHQ-9 score change
Lasso di tempo: 0-6 months after enrollment
Change in score on the 9-item Patient Health Questionnaire
0-6 months after enrollment

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
GAD-7 score change
Lasso di tempo: 0-6 months after enrollment
Change in score on 7-item Generalized Anxiety Disorder scale
0-6 months after enrollment
Quality of Life change
Lasso di tempo: 0-6 months after enrollment
Change in subjective measure of subject's quality of life (based on Behavioral Risk Factor Surveillance System)
0-6 months after enrollment
Workplace productivity change
Lasso di tempo: 0-6 months after enrollment
Change in subjective measure of subject's workplace productivity (based on Behavioral Risk Factor Surveillance System)
0-6 months after enrollment
Medication adherence
Lasso di tempo: 0-6 months after enrollment
Measure of compliance with prescribed medications, based on a single item question
0-6 months after enrollment
Psychotherapy utilization
Lasso di tempo: 12 months prior to enrollment, through 6 months after enrollment
Subjective measurement of whether or not the subject has received psychotherapy from a licensed provider
12 months prior to enrollment, through 6 months after enrollment
Psychiatric specialty utilization
Lasso di tempo: 0-6 months after enrollment
Subjective measurement of whether or not the subject has received treatment from a provider in the Department of Psychiatry
0-6 months after enrollment
Satisfaction with Thrive
Lasso di tempo: 2 months after enrollment
Subjective measurement of how satisfied patient was with the treatment intervention
2 months after enrollment
Satisfaction with Kaiser Permanente Southern California
Lasso di tempo: 0-6 months after enrollment
Subjective measurement of how satisfied patient was with their experience of care at Kaiser Permanente Southern California
0-6 months after enrollment
Thrive Adherence
Lasso di tempo: 0-2 months after enrollment
Percent enrolled in Thrive over total number invited, number of logins and lessons started
0-2 months after enrollment

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Investigatori

  • Investigatore principale: Roderick R Stuart, MD, Southern California Permanente Medical Group

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

13 aprile 2017

Completamento primario (Effettivo)

13 dicembre 2017

Completamento dello studio (Effettivo)

13 dicembre 2017

Date di iscrizione allo studio

Primo inviato

1 febbraio 2017

Primo inviato che soddisfa i criteri di controllo qualità

8 marzo 2017

Primo Inserito (Effettivo)

15 marzo 2017

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

8 marzo 2018

Ultimo aggiornamento inviato che soddisfa i criteri QC

7 marzo 2018

Ultimo verificato

1 marzo 2018

Maggiori informazioni

Termini relativi a questo studio

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi